CHANGE IN RATINGS
upgraded at Goldman to Buy from Neutral. Reaffirming guidance, a robust free cash flow, and a strong balance sheet led to an increase in ratings. Raised price target to $36 from $34.
upgraded at Jefferies from Hold to Buy. $36 price target. Company is the only pure play in farm machinery, and should benefit from economic stimulus in the U.S. and Brazil.
rated new Neutral at Merrill Lynch/Bank of America. $20 price target. Stock looks fairly valued, but the company is a clear market leader and generates steady returns.
downgraded at Citigroup from Buy to Hold. $21 price target. Plant explosion could damage the ability to supply Slim Jim product, which has $200 million of annual revenue. Stock also removed from the Top Picks Live list.
downgraded at Goldman to Buy from Conviction Buy following an increase in key commodity prices. Decreased price target to $63 from $64.
upgraded at KeyBanc to hold, as valuation is attractive. On a historical basis over the last nine years, CYT has traded in an EV/EBITDA multiple average low and high range of 5.2-7.9x or a P/E range of 10.4-17.4x. At current levels (~$21), CYT is trading below its historical average low looking to 2010E outlook, trading at a 2010E EV/EBITDA multiple of 4.5x and a 2010E P/E of 12.2x.
upgraded at Goldman to Neutral from Sell following successful cost cutting measures and higher demand for Q2. Maintained target price of $14.
rated new Buy at Pali Research. $32 price target. Company can generate impressive free cash flow growth.
downgraded at Goldman to Neutral from Buy based on limited upside potential. Maintained target price at $38.
downgraded at KeyBanc. Rating lowered to Hold from Buy. Removes price target. 2009 EPS estimates lowered to 77 cents from 80 cents.
downgraded at Goldman to Sell. Over exposure in California, limited cash flow, and off balance sheet liabilities have brought concern to the co.'s health. Price target lowered to $12 from $15.
downgraded at Goldman to Neutral from Buy. Increasing commodity costs and sector competition led to the decline in ratings. Set target price at $59.
downgraded at Barclays. Rating lowered to Underweight from Equal weight. Price target lowered to $0.25 from $1.00. Maintains 2009 EPS estimates of -$4.60.
upgraded at Credit Suisse to Neutral from Underperform. Cites valuation, a protected balance sheet, and limited risk. Maintained price target of $26.
Mead Johnson Nutrition
upgraded at Goldman to Buy from Neutral. Cites growth in emerging markets and strong profitability. Raised target price to $40 from $33.
downgraded at Credit Suisse to Underperform from Neutral on indications of weak 2Q results. Cites potential challenges of obtaining new orders which would cause the co. to be fully valued at this time. Raises target price to $14 from $12.50.
upgraded at Credit Suisse to Outperform from Neutral based on normalized earnings. With a significant backlog consisting of $10.6B and forecasting the conclusion of many projects indicates much upside potential. Raises target price to $41 from $30.
downgraded at Credit Suisse to Underperform from Neutral based on valuation. Raises target price to $20 from $16.
upgraded at Goldman to Neutral from Sell. Margin improvements, revenue growth, and an improved consulting backdrop led to the upgrade. Increased target price to $5 from $3.
upgraded at Roth to buy as mix shift towards higher growth and margin businesses (RF, broad-based), should cause revenues and margins to expand. Roth believe there is significant share price upside. Price target of $44, based on 25x C10 operating EPS (ex cash) of $1.54 plus $6.11 cash/share.
upgraded at Goldman to Buy from Neutral following better visibility and outlook. Increased price target to $28 from $25.
upgraded at Credit Suisse to Outperform from Neutral. New products, exclusive licenses, and an increasing sales force led to the increase in ratings. Raised target price to $14 from $11.
Total Systems Services
downgraded at Goldman to Sell from Neutral. Prompted by a continued contraction in North American credit card issuance markets, low growth prospects, and high valuation. Increased price target to $12 from $11.
downgraded at Goldman to Neutral from Buy. Indications of tougher sales comparisons and expense pressures led to the decline in numbers. Decreased target price to $56 from $58.
upgraded at Citigroup to Buy. $21 price target. Valuation call, as market share is stabilizing.
STOCK COMMENTS / EPS CHANGES
estimates boosted at Morgan Stanley through 2011. Humira prescription trends have been positive. Overweight rating and $55 price target.
2010 estimates raised at RBC on higher margin assumptions. Company is cutting costs, and still benefiting from the Circuit City bankruptcy. Outperform rating and $44 price target.
estimates, target raised at Friedman, Billings Ramsey. Shares of BRCM now seen reaching $29.50. Channel checks suggest that near-term results could exceed expectations. Outperform rating.
numbers raised at Morgan Stanley to $8.50. Estimates also boosted, to reflect market share gains. Underweight rating.
target increased at FBR to $20 at Friedman, Billings Ramsey. Seller checks have been positive, and the stock still appears attractive on a sum-of-the-parts valuation. Outperform rating.
Research in Motion
estimates raised at Kaufman through 2011. Checks indicate strong selling through VZ. Hold rating and $79 price target.
target raised at Merrill Lynch/Bank of America to $16. Recent channel checks have been good and the company is cutting costs. Buy rating.
target raised at Merrill/BofA to $59. CFO has recently said that volumes have stabilized. Buy rating.
This article was written by a staff member of TheStreet.com.